LSU Health NEW ORLEANS

A CELEBRATION OF INNOVATION

November 9, 2017

presented with support from

BAKER DONELSON

PROGRAM

11:00 AM	Networking
11:15 AM	Welcome and Introduction *Larry H. Hollier, MD, FACS, FACC, FRCS (Eng.)* *Chancellor*
11:20 AM	Keynote Address *Aaron Miscenich* *President, New Orleans BioInnovation Center*
11:30 AM	Awards Presentation *Patrick E. Reed, MS, RTTP* *Director, Office of Technology Management*
Noon	Closing Remarks *Joseph M. Moerschbaecher, III, PhD* *Vice Chancellor for Academic Affairs*
12:15 PM	Luncheon *Chancellor's Dining Room, 3rd Floor*

Ashok Aiyar, PhD

- LIFT^2 Grant, awarded 1/1/17
  "Retroviral vector that permits simultaneous RNAi and protein expression, and related immortalized cell lines"
  Dr. Aiyar is co-developing a technology to generate immortalized cell lines that maintain biological properties over time, allowing for use in reproducible experiments exploring human diseases and relevant therapies.

Suresh K. Alahari, PhD

- LIFT^2 Grant, awarded 7/1/16
  "A potential inhibitor of breast cancer"
  Dr. Alahari is studying the effect of antagomirs on breast cancer growth and metastasis.

Carlos Busso, PhD

- LIFT^2 Grant, awarded 11/1/15
  "Automated hydraulic borer (HYB) for *in situ* lysis of salivary stones"
  Dr. Busso is co-developing a new, cost-effective non-surgical kit for the management of calculi, a medical conditions characterized by the formation of mineral-organic concretions.

Chu Chen, PhD

- Exclusive License Agreement, effective 3/28/16, for a therapeutic compound cocktail for neurodegenerative diseases

Martha L. Cuccia, MPH

- LIFT^2 Grant, awarded 7/1/16
  "Series of science education videos"
  Ms. Cuccia is co-developing a series of science educational videos and cross-platform media aimed at elementary, middle, and high school students.

Shyamal D. Desai, PhD

- US Patent 9,599,626, issued 3/21/17
  "Therapeutic and diagnostic method for ataxia-telangiectasia"
  Dr. Desai has developed a potential therapeutic approach to decrease neurodegeneration in patients with ataxia-telangiectasia.

- LIFT^2 Grant, awarded 5/15/17
  "ISGylation: a potential biomarker for predicting proteinopathy in neurodegenerative diseases"
  Dr. Desai has identified that ISGylation is increased in lymphocytes obtained from patients with various neurodegenerative diseases. She is evaluating ISGylation as a biomarker for the early detection of these diseases.

Jeffrey D. Erickson, PhD

- Nonexclusive License Agreement, effective 6/19/17, for various polyclonal antibodies

Angela Foley, MS, MT (ASCP)

- Exclusive License Agreement, effective 2/25/16, for teaching tools consisting of gross and microscopic images presented in an interactive web environment

Timothy P. Foster, PhD

- LIFT^2 Grant, awarded 7/1/16
  "Development and evaluation of an FDA-IND approved biological as a therapeutic against viral- and inflammation-mediated dermal diseases"
  Dr. Foster is evaluating the ability of topical formulations of peg-ArginaseI to inhibit viral replication while resolving certain inflammatory and pathological processes that result in dermal disease.

Edward L. Grabczyk, PhD

- LIFT^2 Grant, awarded 7/1/16
  "Small molecule induced skipping of MLH3 Exon 7 to slow onset, progression and severity of DNA repeat expansion"
  Dr. Grabczyk is working to validate the use of small molecules to inhibit the expansion of DNA repeats in diseases such as Friedreich ataxia.

Arthur L. Haas, PhD

- US Patent 9,328,341, issued 5/3/16
  "Methods of modulating ubiquitin ligase activity"
  Dr. Haas co-developed a method of modulating the activity of ubiquitin-protein E3 ligase by inhibiting the formation of an E6-Associated Protein (E6AP) polypeptide trimer.

- LIFT^2 Grant, awarded 11/1/15
  "Small Molecule Inhibitors of E6AP/EBE3A as a Potential Therapy for Autism Spectrum Disorder"
  Dr. Haas worked to develop a high throughput assay for E6AP oligomerization to screen chemical libraries to identify second-generation drug leads for HPV- and HCV-associated cervical and hepatic cancers and inherited neurological syndromes.

Daniel S. Haun, MHS

- Exclusive License Agreement, effective 2/25/16, for teaching tools consisting of gross and microscopic images presented in an interactive web environment

Sunyoung Kim, PhD

- LIFT^2 Grant, awarded 1/1/17
  "Protein biomarkers for the diagnosis and prognosis of Necrotizing Enterocolitis"
  Dr. Kim is working to improve performance characteristics of a prototype medical device used to diagnose an inflammatory bowel emergency in infants.

Michael S. Lan, PhD

- US Patent 9,090,907, issued 7/28/15
  "Modified INSM1-promoter for neuroendocrine tumor therapy and diagnostics"
  Dr. Lan co-developed a genetic construct that may be useful for neuroendocrine tumor therapy and diagnosis.

- LIFT^2 Grant, awarded 1/1/17
  "NRSE-Modified INSM1 Promoter Regulated Herpes Simplex Virus Thymidine Kinase Suicide Gene Therapy for Neuroendocrine Tumors"
  Dr. Lan is developing a nasal inhalation delivery system for an engineered genetic construct that can be used for neuroendocrine tumor therapy and diagnosis.

David J. Lefer, PhD

- Exclusive License Agreement, effective 9/23/15, for the use of compounds in treating nitric oxide deficiency disorders and related conditions

Imran N. Mungrue, PhD

- LIFT^2 Grant, awarded 11/1/15
  "A novel method for simultaneous proteome scale protein quantification"
  Dr. Mungrue is working to develop a new manner in which to measure protein levels in a rapid, multiplexed, scalable format.

Donna M. Neumann, PhD

- LIFT^2 Grant, awarded 11/1/15
  "Potent antimicrobial agents against azole resistant fungi based on pyridinohydrazide and hydrazomethylpyridine structural motifs"
  Dr. Neumann performed essential animal model trials of a class of novel and potent antifungal agents that are highly effective against fungal infections resistant to currently marketed antifungal therapies.

Stephanie Pierce, PhD, MN, RN, CNE

- LIFT^2 Grant, awarded 7/1/16
  "Cornerstone of Cultural Competency during the Disaster Cycle Program"
  Dr. Pierce is working to enhance the marketability of an online course for healthcare professionals covering the management and best practices of providing culturally competent care for vulnerable populations during disasters.

Zhiqiang Qin, MD, PhD

- LIFT^2 Grant, awarded 6/15/17
  "Developing new ceramide-analogous 'lead compounds' against AIDS-related lymphomas"
  Dr. Qin plans to assess the anti-AIDS related lymphoma (ARL) activities of newly created synthetic ceramide analogs as "lead compounds" with improved features in xenograft models.

Alison J. Quayle, PhD

- LIFT^2 Grant, awarded 1/1/17
  "Retroviral vector that permits simultaneous RNAi and protein expression, and related immortalized cell lines"
  Dr. Quayle is co-developing a technology to generate immortalized cell lines that maintain biological properties over time, allowing for use in reproducible experiments exploring human diseases and relevant therapies.

- Nonexclusive License Agreement, effective 10/20/16, for an immortalized human endocervical epithelial cell line

Alistair J. Ramsay, PhD

- LIFT^2 Grant, awarded 11/1/15
  "Pneumocystis antigen target for development of novel PC vaccines"
  Dr. Ramsay and others are translating their findings on a vaccine against Pneumocystis, an important cause of pneumonia in HIV-infected individuals, to a mouse model engineered with a human immune system.

Virginia P. Ronchi, PhD

- US Patent 9,328,341, issued 5/3/16 ,
  "Methods of modulating ubiquitin ligase activity"
  Dr. Ronchi co-developed a method of modulating the activity of ubiquitin-protein E3 ligase by inhibiting the formation of an E6-Associated Protein (E6AP) polypeptide trimer.

Judd E. Shellito, MD

- LIFT^2 Grant, awarded 11/1/15
  "Pneumocystis antigen target for development of novel PC vaccines"
  Dr. Shellito and others are translating their findings on a vaccine against Pneumocystis, an important cause of pneumonia in HIV-infected individuals, to a mouse model engineered with a human immune system.

Ann H. Tilton, MD

- Acquisition by Allergan, effective 1/7/16, of an exclusive licensee for a technology using botulinum toxin for the treatment of acne

Fern Tsien, PhD

- LIFT^2 Grant, awarded 7/1/16
  "Series of science education videos"
  Dr. Tsien is co-developing a series of science educational videos and cross-platform media aimed at elementary, middle, and high school students.

Rohan R. Walvekar, MD

- LIFT^2 Grant, awarded 11/1/15
  "Automated hydraulic borer (HYB) for *in situ* lysis of salivary stones"
  Dr. Walvekar is co-developing a new, cost-effective non-surgical kit for the management of calculi, a medical conditions characterized by the formation of mineral-organic concretions.

David A. Welsh, MD

- LIFT^2 Grant, awarded 11/1/15
  "Pneumocystis antigen target for development of novel PC vaccines"
  Dr. Welsh and others are translating their findings on a vaccine against Pneumocystis, an important cause of pneumonia in HIV-infected individuals, to a mouse model engineered with a human immune system.

Eugene A. Woltering, MD, FACS

- US Patent 9,066,959, issued 6/30/15
  "Ficus Extracts having angiogenesis inhibiting activity and methods of isolating and using the same"
  Dr. Woltering co-developed a method for extracting and isolating extracts having angiogenesis inhibiting activity from a latex-containing portion of a Ficus *variant.*

Hong Xin, MD, PhD

- US Patent 9,416,173, issued 8/16/16
  "Peptide and conjugate vaccines for fungal infections"
  Dr. Xin developed monoclonal antibodies that offer passive immunization against candidiasis.

- LIFT^2 Grant, awarded 6/15/17
  "Universal peptide and multi-peptide vaccines against Candida spp. and Aspergillus spp."
  Dr. Xin is working to develop and establish preclinical proof-of-concept for the first universal double-peptide vaccine feasible for human use that protects against invasive fungal infections.

Xiaoming Xu, PhD

- US Patent 9,156,772, issued 10/13/15
  "Fluoride-releasing compositions"
  Dr. Xu developed chelating monomers and fluoride-releasing compositions that may be incorporated into dental materials with high fluoride release rates and high fluoride recharge capabilities.

Office of Technology Management
http://lsuh.sc/otm